Success Story
Edinburgh-based Carcinotech raised £4.2 million as part of its latest funding round and has plans to expand into the US. Using its Carcino3D technology, the startup creates 3D bioprinted tumor models using cancer cell lines derived from patients, providing a platform for rapid, ethical, and accurate drug screening, as well as pre-clinical and personalised medicine testing to support cancer treatment.
| Region/Nation | Scotland |
|---|---|
| Sector | Life Sciences |
| Programme | Investment Fund for Scotland |
| Partner |
Eos Advisory (Eos) led the investment alongside Maven Capital Partners, Scottish Enterprise, Old College Capital, Investing Women, and existing investors TRICAPITAL, SIS Ventures, Gabriel Investment, and Alba Equity. The Maven investment of £750,000 is via the Investment Fund for Scotland, which Maven manages through Maven Equity Finance on behalf of the British Business Bank.
Our vision is to be at the forefront of cancer drug testing and provide personalised medicine testing to every individual suffering from cancer to improve their treatment and chance of survival. Working with global partners, leading pharma companies, surgeons, pathologists, and clinicians, Carcinotech aims to significantly accelerate oncology drug development. Ishani Malhotra CEO and Founder, Carcinotech
Tags related to this content:
Quick links
More success stories
Read a success story about The Padel Club
Founded in 2020, Kris Ball launched The Padel Club after recognising its rising popularity while working abroad. With no courts available in his local area, Wilmslow, Kris decided to start the business in the anticipation that demand for the sport would take off.
Read a success story about The Bucks Head
The first deal from the Investment Fund for Northern Ireland saw fund manager Whiterock facilitate a £100,000 loan to The Bucks Head Inn in Dundrum.
Read a success story about INQDATA
Data solutions company INQDATA received £750,000 in equity investment from the Investment Fund for Northern Ireland in a deal led by Clarendon Fund Managers.